Pfizer, TALAPRO-2, Talazoparib
Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
CD20, Columvi, DLBCL, Genentech
Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell ly..
abiraterone, Lynparza, olaparib, prednisone
Olaparib with abiraterone and prednisone (or prednisolone) is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adults with deleterious or suspected deleterious BRCA-mutated (BR..
DuoBody, Epcoritamab, epkinly, Genmab, IgG1-bispecific antibody
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL that co..
B-cell lymphoma, DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin
Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
May 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Inde..
BMT, Gamida Cell Ltd, hematologic malignancies, Omidubicel
Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
May 2023: Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and older) with hematologic malignancies who are scheduled to recei..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Incyte Corporation, MCC, Merkel cell carcinoma, PODIUM-201, retifanlimab-dlwr, Zynyz
Retifanlimab-dlwr is approved by FDA for metastatic or recurrent locally advanced Merkel cell carcinoma
April 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cell cancer (MCC). In PODIUM-2..
TIL immunotherapy, TILs therapy, Tumor Infiltrating Lymphocytes
Tumor Infiltrating lymphocytes (TIL) Immunotherapy in India
April 2023: Using the body's immune system to fight cancer cells is the goal of the promising cancer treatment method known as tumour infiltrating lymphocytes (TIL) immunotherapy. The process entails taking immune cells called TI..
Abemaciclib, aromatase inhibitor, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with ..